LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide™ platform is a new approach to precise gene insertion that harnesses a cell's natural DNA repair process leading to durable therapeutic protein expression levels. LogicBio's cutting-edge sAAVy™ capsid development platform is designed to support development of treatments in a broad range of indications and tissues. The company is based in Lexington, MA.
Company profile
Ticker
LOGC
Exchange
Website
CEO
Frederic Chereau
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
LOGICBIO AUSTRALIA PTY LIMITED • LOGICBIO SECURITIES CORPORATION ...
IRS number
471514975
LOGC stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
29 Nov 22
EFFECT
Notice of effectiveness
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Nov 22
POS AM
Prospectus update (post-effective amendment)
16 Nov 22
8-K
Termination of a Material Definitive Agreement
16 Nov 22
25-NSE
Exchange delisting
16 Nov 22
SC 14D9/A
Tender offer solicitation (amended)
16 Nov 22
Latest ownership filings
SC 13G/A
Beryl Capital Management LLC
14 Feb 23
SC 13D/A
Arix Bioscience plc
10 Feb 23
4
Mark A Kay
17 Nov 22
4
Mark J Enyedy
17 Nov 22
4
Mariana Nacht
17 Nov 22
4
MICHAEL S WYZGA
17 Nov 22
4
Frederic Chereau
17 Nov 22
4
RICHARD A MOSCICKI
17 Nov 22
4
Jeff Goater
17 Nov 22
4
Daphne Karydas
17 Nov 22
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 31.40 mm | 31.40 mm | 31.40 mm | 31.40 mm | 31.40 mm | 31.40 mm |
Cash burn (monthly) | 2.69 mm | 2.40 mm | 1.93 mm | 2.18 mm | 2.39 mm | 2.11 mm |
Cash used (since last report) | 50.64 mm | 45.20 mm | 36.26 mm | 41.09 mm | 45.08 mm | 39.65 mm |
Cash remaining | -19.24 mm | -13.80 mm | -4.85 mm | -9.69 mm | -13.67 mm | -8.24 mm |
Runway (months of cash) | -7.2 | -5.8 | -2.5 | -4.4 | -5.7 | -3.9 |
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 50 |
Opened positions | 7 |
Closed positions | 6 |
Increased positions | 6 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 179.61 mm |
Total shares | 37.26 mm |
Total puts | 0.00 |
Total calls | 21.50 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Andera Partners | 22.87 mm | $174.53 mm |
Orbimed Advisors | 8.47 mm | $2.97 mm |
Arix Bioscience | 1.83 mm | $1.11 mm |
Ran Nussbaum | 1.50 mm | $0.00 |
Baker Bros. Advisors | 451.48 k | $158.00 k |
Renaissance Technologies | 419.80 k | $147.00 k |
Vanguard | 313.70 k | $110.00 k |
BEN Franklin Resources | 300.00 k | $109.00 k |
Harbor Capital Advisors | 235.29 k | $85.00 k |
BLK Blackrock | 174.45 k | $61.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Nov 22 | Susan Kahn | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.38 | 12,500 | 4.75 k | 0 |
16 Nov 22 | Daniel Gruskin | Common Stock | Sale back to company | Dispose D | No | No | 0 | 3,331 | 0.00 | 0 |
16 Nov 22 | Daniel Gruskin | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.7 | 140,000 | 98.00 k | 0 |
16 Nov 22 | Chen Leon | Common Stock | Sale back to company | Dispose D | No | No | 0 | 22,333 | 0.00 | 0 |
16 Nov 22 | Chen Leon | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.38 | 12,500 | 4.75 k | 0 |
16 Nov 22 | Chen Leon | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.73 | 44,508 | 32.49 k | 0 |
16 Nov 22 | Daphne Karydas | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.38 | 12,500 | 4.75 k | 0 |
16 Nov 22 | Moscicki Richard A | Common Stock | Sale back to company | Dispose D | No | No | 0 | 3,916 | 0.00 | 0 |
16 Nov 22 | Moscicki Richard A | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.38 | 12,500 | 4.75 k | 0 |